MINI REVIEW article

Front. Immunol., 03 July 2025

Sec. Nutritional Immunology

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1598804

Role of TRPV1 in neuroendocrine regulation: a potential target against obesity?

  • School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu,Ā China

Abstract

Obesity is a common metabolic syndrome in which an imbalance between energy intake and consumption is the main cause of excessive accumulation of body fat. The increasing prevalence of obesity and its associated complications poses significant challenges to public health. Activation of the transient receptor potential vanilloid subtype 1 (TRPV1) cascade plays a key role in lipid metabolism and energy intake. TRPV1 is expressed across the central nervous system and peripheral organs is involved in the regulation of hormone secretion, appetite and mitochondrial function, and is recognized as one of the key targets for preventing obesity. The current treatments for obesity exhibit limited efficacy and are associated with numerous side effects. Targeting TRPV1 represents a potentially effective approach for managing obesity. In this work, by combining the recent mechanism of the role of TRPV1 in neuroendocrine regulation, we hope to provide novel approaches to block or even reverse the development of obesity.

1 Introduction

The increasing prevalence of obesity is expected to affect 4 billion people by 2035 (1–3). As a common metabolic syndrome, an imbalance in energy storage and expenditure is the main cause of excessive accumulation of body fat (4–7). Recent studies have shown that neuroendocrine modulation plays an important role in regulating adipose tissue thermogenesis and lipid metabolism (8). Body weight homeostasis is regulated by the coordinated interactions of nutrients, circulating neuroendocrine hormones, the central nervous system, and peripheral nerves, and even the release of hormonal signals from endocrine tissues is largely regulated by the peripheral nervous system (PNS) (9–13). Sympathetic nervous system (SNS) innervation of adipose tissue has been demonstrated in recent studies (14–16), and activation of the SNS prevents obesity by promoting brown fat thermogenesis and energy expenditure via the hypothalamic neuropeptide Y and norepinephrine. The SNS is an integral part of metabolism-related organs, but our understanding of the mechanisms by which the nervous system regulates the endocrine system to affect obesity is still lacking. understanding.

Activation of transient receptor potential vanilloid subtype 1 (TRPV1) sustains centrally regulated thermogenesis in peripheral tissues. TRPV1 is a nonselective cation channel (17). TRPV1 has a tetrameric structure consisting of three parts, the N-terminus and C-terminus located intracellularly, and six transmembrane regions (S1–S6) (18–20), with the N-terminal end playing a role in the activation of the channel. Early studies of TRPV1 focused on thermal and inflammatory pain transmission, and recent studies have revealed that TRPV1 also plays an important role in the regulation of tissue energy metabolism. A study of TRPV1 involvement in white adipose tissue (WAT) browning revealed (21) that the gene levels of TRPV1, silent message regulator 1 (Sirt1), and uncoupling protein-1 (UCP1) were suppressed in high-fat diet-fed mice, whereas capsaicin-fed mice presented a reversal of the expression levels of all these genes. Increasing evidence suggests that TRPV1 plays a key role in the regulation of body weight and lipid metabolism and is therefore considered a potential target for the treatment of obesity (22–26).

Given the increasing incidence of obesity annually, the resulting complications place heavy psychological and economic pressure on patients. Therefore, revealing the neuroendocrine regulatory mechanism of TRPV1 in obesity is particularly important. This paper reveals the core mechanism of TRPV1 in the endocrine system and the central nervous system of obese patients by reviewing previous studies on obesity and TRPV1 to provide a theoretical basis for stopping or even reversing obesity.

2 The potential role of TRPV1 in obesity

2.1 Neuromodulatory mechanisms of TRPV1

2.1.1 Regulation of feeding behavior and energy metabolism by TRPV1 activation in the central nervous system

The TRPV1 protein in the central nervous system (CNS) plays an important role in the regulation of feeding behavior. TRPV1-positive neurons are widely distributed in the CNS (27–30), especially in the hypothalamus and nucleus tractus solitarius (NTS), which are closely related to food intake and energy expenditure (31, 32). TRPV1 expression in the hypothalamus of high-fat diet (HFD)-fed mice was significantly downregulated (33), whereas capsaicin restored its expression level, and activation of TRPV1 was able to increase energy expenditure and reduce body weight.

The function of TRPV1 is related to its distribution. In the hypothalamus, TRPV1-positive neurons coexpress a variety of neuropeptides [including calcitonin gene-related peptide (CGRP), NPY, and substance P (SP)] to regulate peripheral thermogenesis and dietary intake (33). TRPV1 activation induces Ca2+ influx, which may be crucial for the release and function of CGRP (34, 35), and CGRP may inhibit food intake by increasing cyclic adenosine monophosphate (cAMP) and cholecystokinin (CCK) expression in the hypothalamus, downregulating the expression of appetite-inducing neuropeptides (NPY and MCH), and increasing skin temperature and brown adipose tissue (BAT) thermogenesis (34, 36). In POMC neurons, which regulate appetite and satiety, TRPV1 activation releases α-melanocyte-stimulating hormone (α-MSH) to act on satiety centers, leading to a reduction in appetite (37), and this process is TRPV1 dependent. In terms of hypothalamic gene expression profiles in HFD-fed mice, TRPV1 activation upregulates the expression of satiety-related neuropeptide genes (e.g., UCN, PYY, RAMP3, GRP, BDNF, and CARTPT) and downregulates the expression of appetite-stimulating genes (e.g., CNR1, GALR1, GHRL, ADRA2B, and GHSR), reducing food intake and body weight (33, 38–41). (FigureĀ 1).

FigureĀ 1

Activation of TRPV1 in the solitary tract nucleus (NTS) inhibits BAT activation in HFD-fed rats. The levels of linoleic acid metabolites (LAs) are elevated in the NTS of HFD-fed rats, and these metabolites can act as endogenous TRPV1 activators (42). The activation of TRPV1 at the afferent terminals of the vagus nerve induced the release of glutamate to increase the activity of the neurons in the NTS, which in turn inhibited the sympathetic excitatory neurons of the BAT, forming a pathway to inhibit brown adipose tissue (BAT) thermogenesis and energy expenditure. pathway. Therefore, the energy metabolism regulatory function of TRPV1 is spatially inhibitory (FigureĀ 1).

2.1.2 Central regulation of tissue energy metabolism is dependent on activation of TRPV1 in peripheral sensory nerves

Peripheral sensory nerves are involved in regulating adipose tissue thermogenesis and WAT browning processes. Studies have shown that BAT-specific denervation in rats is associated with increased body weight; decreased resting metabolic rates; decreased BAT mass; decreased adipocyte and mitochondrial numbers; downregulated UCP1 protein expression; and decreased core body temperature (43–45). In contrast, both unilateral and bilateral ablation of subcutaneous WAT in mice upregulated the expression of thermogenic genes and was accompanied by beige adipocyte formation (8). These findings suggest that neuromodulation is necessary to maintain the homeostasis of fat energy metabolism.

The regulation of energy metabolism in adipose tissue is dependent on neuropeptide secretion following TRPV1 activation. Mammalian adipose tissue function is regulated by the peripheral nervous system (8), and the activation of TRPV1 in BAT and WAT sensory neurons results in the expression of the neuropeptides CGRP and SP (46, 47), which transmit information from adipose tissue to the central nervous system (hypothalamus, solitary tract nucleus, etc.) through synaptic links between neurons, and the removal of sensory nerves of the adipose tissue results in compensatory hyperplasia, further demonstrating the involvement of sensory signaling in systemic adipose homeostasis (48, 49). Tracing of sympathetic nerves and sensory nerves innervating the BAT revealed colocalization in the central nervous system (hypothalamus, solitary tract nucleus, and other brain regions) (49, 50), suggesting that there is a direct interaction between sympathetic and sensory signals at the center. Thus, sympathetic and sensory nerves synergistically regulate fat metabolism through a bidirectional loop, with sympathetic nerves dominating lipolysis and thermogenesis and sensory nerves feeding back on fat status to modulate sympathetic output, a mechanism that is functionally specific in WAT and BAT but shares some central nodes.

In addition, the neuropeptides CGRP and SP released upon sensory nerve activation exert regulatory effects on adipose tissue metabolism. Previous studies have shown that CGRP has hormonal effects as a neuropeptide (51). Lipid metabolism regulation by CGRP may occur through changes in plasma catecholamine, cortisol, glucagon, insulin, lactate, and adipokine levels, as well as in the blood supply of adipose tissue (36, 52–60). SP upregulates neurokinin 1 receptor (NK1R) mRNA and protein expression levels in human preadipocytes (61). SP also promotes lipolysis in 3T3L1 adipocytes, blocks insulin-mediated fatty acid uptake, and inhibits the accumulation of lipid droplets during differentiation (62). In contrast, high-fat diet-induced weight gain was inhibited in NK1R-/- mice, circulating levels of insulin and leptin were reduced, and insulin-dependent glucose uptake was improved (63). Thus, neuropeptides secreted upon the activation of sensory nerve TRPV1 not only play a role in central regulation but also play a role in regulating local adipose tissue (FigureĀ 1).

2.2 Endocrine regulatory mechanisms of TRPV1

2.2.1 Adipose tissue TRPV1 activation promotes mitochondrial oxidation

Adipose tissue is an important part of the human body. Owing to its structure and function, it can be divided into WAT, which is responsible for storing fat, maintaining body temperature and regulating metabolism throughout the body, and BAT, which generates a large amount of heat energy through the catabolism and oxidation of lipids and helps to maintain body temperature.

Adipose tissue TRPV1 activation to promote mitochondrial energy metabolism is required for WAT browning. WAT browning has been used as a novel strategy to improve metabolic health (6), and WAT browning is able to inhibit energy intake-induced weight loss by triggering thermogenesis to promote energy expenditure (40, 64, 65). Upon the activation of WAT-expressed TRPV1 (66, 67), the intracellular Ca2+ concentration increases, and the activation of calmodulin kinase II (CaMKII) causes the phosphorylation of AMP protein kinase (AMPK), leading to the activation of sirtuin 1 (SIRT-1), which serves as a sensor of cellular metabolism and energy utilization (68, 69), the activation of which leads to the deacetylation of PPARγ and PRDM-16, both of which promote WAT browning (70, 71). With the activation of TRPV1, the expression of UCP-1 and bone morphogenetic protein 8B (BMP8B) is upregulated. UCP-1 is localized on the inner mitochondrial membrane, and when activated, it short-circuits the mitochondrial proton gradient, thus promoting thermogenesis (66, 72). By increasing p38 MAPK/CREB signaling and adiponectin activity, BMP8B enhances the sensitivity of BAT to NE to promote energy expenditure (73). Upon activation of TRPV1, the mitochondrial deacetylase SIRT-3 is activated, leading to a decrease in ROS production (74) and an increase in energy metabolism due to increased mitochondrial activity. SIRT-3 was also able to downregulate the expression of H3K27ac on the mitochondrial calcium unidirectional transporter (MCU) promoter via an AMPK-dependent pathway, which inhibited mitochondrial calcium ion overload to prevent BAT whitening. The expression of the adipogenic regulators Pparγ2 and PPARγ coactivator 1α (Pgc-1α) in BAT is also upregulated upon activation of TRPV1 (75). Pparγ2 promotes transcriptional cascades involved in adipocyte function (76, 77), whereas Pgc-1α stimulates mitochondrial biogenesis as well as BAT cell function, including transcriptional activation of Ucp1 (78). Mitochondrial homeostasis in BAT is critical for maintaining BAT thermogenesis, and mitochondrial Ca2+ regulates the activity of essential metabolic enzymes and transporter proteins (79). TRPV1 maintains mitochondrial Ca2+ homeostasis in BAT by repressing the expression of the ion channel protein LETM1 (80). When genes regulating TRPV1 expression are knocked down, the expression of UCP1 and LETM1 tends to increase, leading to disturbances in mitochondrial Ca2+ homeostasis in BAT and aggravating obesity (Figure 2).

FigureĀ 2

Studies have shown that TRPV1 activation in murine and human adipose precursor cells upregulates the cytoplasmic receptor responsible for calcium cycling (α1-AR), the calcium-sensing enzyme (CaMKII), and mitochondrial calcium transporters (VDAC and MCU), leading to increased intracellular Ca²+ concentrations, which suppress adipogenesis in adipose precursor cells and promote UCP1-dependent thermogenesis (81, 82). Following the activation of TRPV1, the mRNA levels of hormone-sensitive lipase (HSL), carnitine palmitoyltransferase Ia (CPT-Ia), which is a rate-limiting enzyme in mitochondrial fatty acid oxidation, and uncoupling protein 2 (UCP2) are increased (83–86). This results in increased lipolysis in adipocytes and a reduction in the intracellular lipid content (FigureĀ 2).

2.2.2 Pancreatic β-cell TRPV1 activation regulates pancreatic function

The pancreas is an important visceral organ in the regulation of glucose metabolism, and insulin, an anabolic hormone, is synthesized and secreted by pancreatic beta cells (87). In peripheral tissues, insulin promotes glucose uptake in adipose tissue and inhibits lipolysis, promoting fat storage in adipocytes (88, 89), and in the central nervous system, insulin acts as an appetite suppressant to decrease food intake and body weight (90).

TRPV1 activation in pancreatic β-cells increases insulin secretion. Previous studies have shown that TRPV1 affects pancreatic function and insulin secretion in both humans and animals (91), and the activation of TRPV1 expressed on pancreatic β-cells by calcium influx increases insulin secretion, a process that involves the regulation of protein kinase C alpha (PKC alpha) and cyclic adenosine monophosphate cAMP (92, 93). In addition, TRPV1 is coexpressed with CGRP in pancreatic nerve fibers (94), and inhibition of TRPV1 signaling decreases CGRP secretion, thereby increasing insulin secretion. Insulin sensitizes TRPV1 in sensory nerve endings (95, 96), and TRPV1-activated neurons regulate pancreatic β-cell function through the release of neuropeptides such as SP and CGRP (97–100), where an increase in CGRP secretion decreases insulin release from pancreatic β-cells (98). Sustained high levels of circulating CGRP can lead to insulin resistance and obesity, whereas increased SP secretion can alleviate insulin resistance (97). Furthermore, TRPV1 is coexpressed with CCK-sensitive vagal afferent neurons. Studies have revealed that TRPV1 activation-induced calcium influx enhances the responsiveness of vagal afferent neurons to CCK, leading to increased vagal signaling, which regulates pancreatic secretory function to maintain metabolic homeostasis. This mechanism may involve low-affinity CCK binding to CCK1 receptors (CCK1Rs), triggering downstream signaling (e.g., Gq proteins or β-arrestin) (101). Recent studies have indicated that TRPV1 activation may contribute to β-cell dysfunction and acute pancreatitis, whereas TRPV1 antagonists restore SP/CGRP expression levels, increase the islet area, reduce pancreatic β-cell vacuolization, decrease proinflammatory cytokine (TNF-α, IL-1β) release, and increase anti-inflammatory IL-10 secretion (102). This process may involve the modulation of the JAK2-STAT3 signaling pathway (103). (FigureĀ 2).

2.2.3 Regulation of energy metabolism by adrenal TRPV1 activation

The adrenal gland is composed of the cortex and medulla and is involved in the regulation of energy metabolism as an endocrine gland (104). The adrenal cortex synthesizes and secretes steroids, whereas the medulla produces catecholamines and neuropeptides (105–107). Epinephrine and norepinephrine maintain energy production through lipolysis and ketogenesis during hypoglycemia and malnutrition (108–110). Catecholamine binding stimulates β3-adrenergic receptors, leading to increased intracellular cAMP concentrations and the activation of cyclic AMP-dependent protein kinase A (PKA), which leads to the phosphorylation and activation of hormone-sensitive lipase (HSL) to increase adipocyte lipolysis (111). In addition, catecholamine stimulation of α2-adrenergic receptors inhibits lipolysis (112). These adrenergic responses depend on the density of these two receptor families, their relative affinities, and the location and amount of adipose tissue (113). Obesity may alter the sensitivity of alpha- and beta-adrenergic receptors in adipose tissue, thereby altering the effects of catecholamines on lipolytic processes and increasing fat storage (114, 115). Glucocorticoids (GCS) plays an important role in the regulation of metabolic homeostasis (116). Chronical elevation of GCs can alter body fat distribution, increasing visceral obesity and metabolic abnormalities (117, 118). (FigureĀ 2).

TRPV1 plays an important role in metabolic pathways related to energy homeostasis and insulin signaling. In the rat adrenal gland, there are TRPV1-positive nerve fibers; in particular, TRPV1-positive fibers are observed in the adrenal tegument, cortex and medulla (119), where 35% of the medullary cells and 20% of the cortical cells express this cation channel (120). The colocalization of TRPV1 in the adrenal medulla with CGRP, which is stored in sensory nerve endings, is associated with pain perception, inflammatory responses and increased catecholamine secretion in the adrenal medulla (121, 122). Catecholamines serve as an important class of neurotransmitters and hormones, including epinephrine, norepinephrine, and dopamine, which play key roles in the regulation of the nervous system, cardiovascular system, and energy metabolism (123). Sensory nerves expressing TRPV1 promote energy expenditure by activating sympathetic nerves and promoting noradrenaline secretion (124).

TRPV1 channels may be activated by acidic contents released by adrenal medullary cells (125), and synergistically with the activation of P2X3 receptors, they lead to the secretion of catecholamine hormones by the adrenal medulla. After the activation of TRPV1, the secretion of norepinephrine is stimulated via β2 adrenergic receptors and β3 adrenergic receptors, which increase the expression of UCP1 in BAT. This leads to a reduction in visceral fat content in obese rats induced by a high-fat diet (78, 126, 127). BAT plays a major role in diet-induced thermogenesis, and UCP1 is thought to be a key thermogenic regulator of BAT (78). Previous studies have demonstrated that the activation of TPPV1 enhances the secretion of epinephrine (128, 129), which increases energy expenditure and thermogenesis through the activation of adrenergic receptors (130, 131), whereas in adrenal-depleted rats, thermogenesis resulting from TPPV1 activation is markedly attenuated (132). In addition, adrenergic receptor activation upregulated UCP1 expression in BAT, increasing WAT browning and BAT thermogenesis (78, 133–140). In addition, TRPV1 activation in adrenocortical cells leads to an increase in intracellular calcium ion levels, which in turn inhibits GC secretion, reducing the occurrence of visceral obesity (141). (FigureĀ 2).

3 TRPV1-targeted therapy

At this stage, the treatment strategy for obesity still emphasizes lifestyle changes, such as avoiding a sedentary lifestyle, proper exercise and a balanced diet. However, the incidence of obesity remains high. Previous studies on TRPV1-targeted therapy have focused mostly on relieving discomfort, such as pain and itching caused by the disease (142, 143), and with increasing research, TRPV1 has been recognized as a potential target with preventive effects against obesity (25). TRPV1 plays an important role in the regulation of pain sensation, body heat production and energy metabolism. In previous clinical trials, the use of TRPV1 antagonists increased the thermal threshold and increased the risk of burns, which makes it difficult for related drugs to enter clinical phase III trials (144). Most TRPV1 antagonists used in clinical studies involve varying degrees of body temperature elevation in experimental subjects. Most TRPV1 antagonists have shown different degrees of temperature elevation in subjects in clinical studies (144, 145), and their molecular mechanisms are still poorly understood. Moreover, TRPV1 agonists such as capsaicin have been shown to induce a decrease in body temperature in animal studies (146). In a related study, resveratrol significantly improved the discomfort induced by TRPV1 agonists (147), suggesting that these side effects could be avoided or even eliminated. A new generation of TRPV1 antagonists has been reported to have a weaker effect on body temperature in clinical trials (148). The clinically safe TRPV1 antagonist XEN-D0501 is currently under development as an oral drug for overactive bladder (148); undoubtedly, these findings provide valuable clinical data for the development of TRPV1-targeted drugs to treat obesity.

4 Conclusion

Obesity is a metabolic syndrome characterized by excessive accumulation of fat in the body due to an imbalance between energy intake and expenditure. In previous studies, conventional treatments for obesity included lifestyle interventions (such as dietary restrictions and physical exercise), bariatric surgery, and drug therapy (149). At present, the drugs commonly used in clinical practice for treating obesity all have certain efficacy, but most of them cause various side effects (150). In this review, by summarizing the mechanism of the role of TRPV1 in the endocrine system and the central nervous system under conditions of obesity, we found that TRPV1 plays an important role in the occurrence and development of obesity and participates in the processes of energy intake and consumption. Strict control of energy homeostasis is crucial for maintaining a healthy weight or for helping with weight loss by expending more energy than is consumed. TRPV1 is involved in energy homeostasis, regulating both food intake and energy expenditure. TRPV1 may affect appetite by controlling the levels of appetite hormones, and it can also increase energy expenditure by generating heat.

TRPV1, a nonselective cation channel, is also an important receptor. The acute activation of TRPV1 leads to conformational changes in TRPV1, causing the opening of the TRPV1 channel, resulting in a large influx of Ca²+ and Na+, triggering cell depolarization. The influx of Ca²+ prompts sensory nerve endings to release CGRP and SP, mediating neurogenic inflammation (vasodilation, plasma extravasation). Chronic activation of TRPV1 (such as long-term exposure to capsaicin or inflammatory stimuli) causes changes in the phosphorylation state of TRPV1, leading to channel desensitization. Research has shown that normal rats typically lose weight after long-term capsaicin desensitization, and this process is associated with a reduction in fat accumulation (81, 151). Long-term activation of TRPV1 can also increase energy expenditure by enhancing the thermogenic capacity of brown adipose tissue and promoting the browning of white adipose tissue (67, 152). After capsaicin activates TRPV1, it increases the abundance of beneficial bacteria in the intestine, promoting the production of bile acids (BAs) and short-chain fatty acids (SCFAs) and increasing the secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), thereby increasing satiety, reducing food intake, and influencing energy metabolism and inflammatory responses (153, 154). Furthermore, obesity, a form of chronic inflammation, increases the circulating levels of fat and inflammatory cytokines (155, 156). The activation of TRPV1 is regulated by various inflammatory mediators, including nerve growth factor (NGF), prostaglandins (PGs), bradykinin (BK), leukotrienes (LTB4), etc. These mediators increase the sensitivity of TRPV1 through different signaling pathways (such as PKA, PKC, and MAPK), thereby activating TRPV1 (157, 158). When TRPV1 is activated, it regulates downstream pathways and participates in the regulation of obesity. The acute activation of TRPV1 serves as a warning system for the body to avoid harm (such as burns), whereas chronic activation induces adaptive protection (such as maintaining vascular homeostasis, anti-inflammatory desensitization, and metabolic regulation). Therefore, chronic activation of TRPV1 has broader application potential for metabolic diseases.

Although a large body of evidence points to a relationship between the development of obesity and TRPV1, the relationship between the two is still controversial in some studies. For example, TRPV1 knockout mice have been reported to lose body weight (22), but other studies have shown that TRPV1 knockout mice are not obese at young ages. However, the weight of TRPV1 knockout mice increases significantly during aging (159). These findings suggest that the regulatory effect of TRPV1 on obesity may be age dependent, and a similar relationship was also shown in healthy subjects (160). Therefore, age should be considered a potential influencing factor in the study of TRPV1 and obesity. Nevertheless, aberrant TRPV1 activation and expression may contribute to the onset and development of obesity. Therefore, TRPV1 may be a target for the treatment of weight loss disorders, and finding a drug or stimulation method (mechanical stimulation or temperature stimulation) that can treat obesity by acting on TRPV1 will be our next research direction.

Statements

Author contributions

JW: Writing – original draft, Writing – review & editing, Investigation, Conceptualization. ML: Writing – review & editing. LW: Writing – review & editing. PX: Writing – review & editing. JC: Writing – review & editing. XX: Supervision, Conceptualization, Writing – review & editing. WD: Writing – review & editing, Methodology, Conceptualization.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This work is supported by the National Natural Science Foundation of China (No. 82374176) and the Sichuan Science and Technology Program (No. 2023ZYD0048).

Acknowledgments

The image production in the article was created with Biorender.com.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1

    Organization WH. One in eight people are now living with obesity(2024). Available online at: https://www.who.int/news/item/01-03-2024-one-in-eight-people-are-now-living-with-obesity (Accessed April 20, 2024).

  • 2

    KellyTYangWChenCSReynoldsKHeJ. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). (2008) 32:1431–7. doi:Ā 10.1038/ijo.2008.102

  • 3

    SaeedSBonnefondAFroguelP. Obesity: exploring its connection to brain function through genetic and genomic perspectives. Mol Psychiatry. (2024) 30:651–8. doi:Ā 10.1038/s41380-024-02737-9

  • 4

    ZhouHGizlenciMXiaoYMartinFNakamoriKZicariEMet al. Obesity-associated inflammation and alloimmunity. Transplantation. (2024) 109:588–96. doi:Ā 10.1097/TP.0000000000005183

  • 5

    KwokKHLamKSXuA. Heterogeneity of white adipose tissue: molecular basis and clinical implications. Exp Mol Med. (2016) 48:e215. doi:Ā 10.1038/emm.2016.5

  • 6

    BarteltAHeerenJ. Adipose tissue browning and metabolic health. Nat Rev Endocrinol. (2014) 10:24–36. doi:Ā 10.1038/nrendo.2013.204

  • 7

    CohenPKajimuraS. The cellular and functional complexity of thermogenic fat. Nat Rev Mol Cell Biol. (2021) 22:393–409. doi:Ā 10.1038/s41580-021-00350-0

  • 8

    WangYLeungVHZhangYNudellVSLoudMServin-VencesMRet al. The role of somatosensory innervation of adipose tissues. Nature. (2022) 609:569–74. doi:Ā 10.1038/s41586-022-05137-7

  • 9

    TownsendKL. One nervous system: critical links between central and peripheral nervous system health and implications for obesity and diabetes. Diabetes. (2024) 73:1967–75. doi:Ā 10.2337/dbi24-0004

  • 10

    RenWChenJWangWLiQYinXZhuangGet al. Sympathetic nerve-enteroendocrine L cell communication modulates GLP-1 release, brain glucose utilization, and cognitive function. Neuron. (2024) 112:972–90.e8. doi:Ā 10.1016/j.neuron.2023.12.012

  • 11

    AlcantaraICTapiaAPMAponteYKrashesMJ. Acts of appetite: neural circuits governing the appetitive, consummatory, and terminating phases of feeding. Nat Metab. (2022) 4:836–47. doi:Ā 10.1038/s42255-022-00611-y

  • 12

    GautronLElmquistJKWilliamsKW. Neural control of energy balance: translating circuits to therapies. Cell. (2015) 161:133–45. doi:Ā 10.1016/j.cell.2015.02.023

  • 13

    BlüherM. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. (2019) 15:288–98. doi:Ā 10.1038/s41574-019-0176-8

  • 14

    BartnessTJLiuYShresthaYBRyuV. Neural innervation of white adipose tissue and the control of lipolysis. Front Neuroendocrinol. (2014) 35:473–93. doi:Ā 10.1016/j.yfrne.2014.04.001

  • 15

    Freire-AgulleiroƓLópezM. Sympathetic NPY ignites adipose tissue. Neuron. (2024) 112:3816–8. doi:Ā 10.1016/j.neuron.2024.11.004

  • 16

    CuiXJingJWuRCaoQLiFLiKet al. Adipose tissue-derived neurotrophic factor 3 regulates sympathetic innervation and thermogenesis in adipose tissue. Nat Commun. (2021) 12:5362. doi:Ā 10.1038/s41467-021-25766-2

  • 17

    CaterinaMJSchumacherMATominagaMRosenTALevineJDJuliusD. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. (1997) 389:816–24. doi:Ā 10.1038/39807

  • 18

    ZhaoRTsangSY. Versatile roles of intracellularly located TRPV1 channel. J Cell Physiol. (2017) 232:1957–65. doi:Ā 10.1002/jcp.25704

  • 19

    CaoELiaoMChengYJuliusD. TRPV1 structures in distinct conformations reveal activation mechanisms. Nature. (2013) 504:113–8. doi:Ā 10.1038/nature12823

  • 20

    LiaoMCaoEJuliusDChengY. Structure of the TRPV1 ion channel determined by electron cryo-microscopy. Nature. (2013) 504:107–12. doi:Ā 10.1038/nature12822

  • 21

    BaskaranPCovingtonKBennisJMohandassALehmannTThyagarajanB. Binding efficacy and thermogenic efficiency of pungent and nonpungent analogs of capsaicin. Molecules. (2018) 23:3198. doi:Ā 10.3390/molecules23123198

  • 22

    MotterALAhernGP. TRPV1-null mice are protected from diet-induced obesity. FEBS Lett. (2008) 582:2257–62. doi:Ā 10.1016/j.febslet.2008.05.021

  • 23

    ChenJLiLLiYLiangXSunQYuHet al. Activation of TRPV1 channel by dietary capsaicin improves visceral fat remodeling through connexin43-mediated Ca2+ influx. Cardiovasc Diabetol. (2015) 14:22. doi:Ā 10.1186/s12933-015-0183-6

  • 24

    SunFXiongSZhuZ. Dietary capsaicin protects cardiometabolic organs from dysfunction. Nutrients. (2016) 8:174. doi:Ā 10.3390/nu8050174

  • 25

    LudyMJMattesRD. Comparison of sensory, physiological, personality, and cultural attributes in regular spicy food users and non-users. Appetite. (2012) 58:19–27. doi:Ā 10.1016/j.appet.2011.09.018

  • 26

    MaLZhongJZhaoZLuoZMaSSunJet al. Activation of TRPV1 reduces vascular lipid accumulation and attenuates atherosclerosis. Cardiovasc Res. (2011) 92:504–13. doi:Ā 10.1093/cvr/cvr245

  • 27

    MezeyETóthZECortrightDNArzubiMKKrauseJEEldeRet al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A. (2000) 97:3655–60. doi:Ā 10.1073/pnas.97.7.3655

  • 28

    SudburyJRBourqueCW. Dynamic and permissive roles of TRPV1 and TRPV4 channels for thermosensation in mouse supraoptic magnocellular neurosecretory neurons. J Neurosci. (2013) 33:17160–5. doi:Ā 10.1523/JNEUROSCI.1048-13.2013

  • 29

    RobertsJCDavisJBBenhamCD. 3H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution. Brain Res. (2004) 995:176–83. doi:Ā 10.1016/j.brainres.2003.10.001

  • 30

    InprasitCHuangYCLinYW. Evidence for acupoint catgut embedding treatment and TRPV1 gene deletion increasing weight control in murine model. Int J Mol Med. (2020) 45:779–92. doi:Ā 10.3892/ijmm.2020.4462

  • 31

    CoveleskieKKilpatrickLAGuptaAStainsJConnollyLLabusJSet al. The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity. Obes Sci Pract. (2017) 3:434–45. doi:Ā 10.1002/osp4.124

  • 32

    LockieSH. Glucagon-like peptide-1 receptor in the brain: role in neuroendocrine control of energy metabolism and treatment target for obesity. J Neuroendocrinol. (2013) 25:597–604. doi:Ā 10.1111/jne.12039

  • 33

    BabootaRKMurtazaNJagtapSSinghDPKarmaseAKaurJet al. Capsaicin-induced transcriptional changes in hypothalamus and alterations in gut microbial count in high fat diet fed mice. J Nutr Biochem. (2014) 25:893–902. doi:Ā 10.1016/j.jnutbio.2014.04.004

  • 34

    LimaWGMarques-OliveiraGHda SilvaTMChavesVE. Role of calcitonin gene-related peptide in energy metabolism. Endocrine. (2017) 58:3–13. doi:Ā 10.1007/s12020-017-1404-4

  • 35

    MinowaSTsuchiyaSSomeyaAHorieSMurayamaT. Role of neuropeptide receptor systems in vanilloid VR1 receptor-mediated gastric acid secretion in rat brain. Eur J Pharmacol. (2004) 486:317–24. doi:Ā 10.1016/j.ejphar.2004.01.006

  • 36

    SunJYJingMYWangJFWengXY. The approach to the mechanism of calcitonin gene-related peptide-inducing inhibition of food intake. J Anim Physiol Anim Nutr (Berl). (2010) 94:552–60. doi:Ā 10.1111/j.1439-0396.2009.00937.x

  • 37

    VicentMAMookCLCarterME. POMC neurons in heat: A link between warm temperatures and appetite suppression. PloS Biol. (2018) 16:e2006188. doi:Ā 10.1371/journal.pbio.2006188

  • 38

    RiosM. BDNF and the central control of feeding: accidental bystander or essential player? Trends Neurosci. (2013) 36:83–90. doi: 10.1016/j.tins.2012.12.009

  • 39

    LiaoGYAnJJGharamiKWaterhouseEGVanevskiFJonesKRet al. Dendritically targeted Bdnf mRNA is essential for energy balance and response to leptin. Nat Med. (2012) 18:564–71. doi:Ā 10.1038/nm.2687

  • 40

    CaoLChoiEYLiuXMartinAWangCXuXet al. White to brown fat phenotypic switch induced by genetic and environmental activation of a hypothalamic-adipocyte axis. Cell Metab. (2011) 14:324–38. doi:Ā 10.1016/j.cmet.2011.06.020

  • 41

    KaurJKumarVKumarVShafiSKharePMahajanNet al. Combination of TRP channel dietary agonists induces energy expending and glucose utilizing phenotype in HFD-fed mice. Int J Obes (Lond). (2022) 46:153–61. doi:Ā 10.1038/s41366-021-00967-3

  • 42

    ConceiçãoEPSReynoldsCAMorrisonSFMaddenCJ. Activation of transient receptor potential vanilloid 1 channels in the nucleus of the solitary tract and activation of dynorphin input to the median preoptic nucleus contribute to impaired BAT thermogenesis in diet-induced obesity. eNeuro. (2021) 8:ENEURO.0048-21.2021. doi: 10.1523/ENEURO.0048-21.2021

  • 43

    Himms-HagenJCuiJLynn SigurdsonS. Sympathetic and sensory nerves in control of growth of brown adipose tissue: Effects of denervation and of capsaicin. Neurochem Int. (1990) 17:271–9. doi:Ā 10.1016/0197-0186(90)90149-N

  • 44

    VaughanCHBartnessTJ. Anterograde transneuronal viral tract tracing reveals central sensory circuits from brown fat and sensory denervation alters its thermogenic responses. Am J Physiol Regul Integr Comp Physiol. (2012) 302:R1049–58. doi:Ā 10.1152/ajpregu.00640.2011

  • 45

    CuiJHimms-HagenJ. Long-term decrease in body fat and in brown adipose tissue in capsaicin-desensitized rats. Am J Physiol. (1992) 262:R568–73. doi:Ā 10.1152/ajpregu.1992.262.4.R568

  • 46

    KobayashiKFukuokaTObataKYamanakaHDaiYTokunagaAet al. Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat primary afferent neurons with adelta/c-fibers and colocalization with trk receptors. J Comp Neurol. (2005) 493:596–606. doi:Ā 10.1002/cne.20794

  • 47

    JuliusD. TRP channels and pain. Annu Rev Cell Dev Biol. (2013) 29:355–84. doi:Ā 10.1146/annurev-cellbio-101011-155833

  • 48

    HarrisRBS. Denervation as a tool for testing sympathetic control of white adipose tissue. Physiol Behav. (2018) 190:3–10. doi:Ā 10.1016/j.physbeh.2017.07.008

  • 49

    RyuVGarretsonJTLiuYVaughanCHBartnessTJ. Brown adipose tissue has sympathetic-sensory feedback circuits. J Neurosci. (2015) 35:2181–90. doi:Ā 10.1523/JNEUROSCI.3306-14.2015

  • 50

    GarretsonJTSzymanskiLASchwartzGJXueBRyuVBartnessTJ. Lipolysis sensation by white fat afferent nerves triggers brown fat thermogenesis. Mol Metab. (2016) 5:626–34. doi:Ā 10.1016/j.molmet.2016.06.013

  • 51

    KrugerLMantyhPWSterniniCBrechaNCMantyhCR. Calcitonin gene-related peptide (CGRP) in the rat central nervous system: patterns of immunoreactivity and receptor binding sites. Brain Res. (1988) 463:223–44. doi:Ā 10.1016/0006-8993(88)90395-2

  • 52

    MatsuiSYamaneTKobayashi-HattoriKOishiY. Ultraviolet B irradiation reduces the expression of adiponectin in ovarial adipose tissues through endocrine actions of calcitonin gene-related peptide-induced serum amyloid A. PloS One. (2014) 9:e98040. doi:Ā 10.1371/journal.pone.0098040

  • 53

    BrainSDWilliamsTJTippinsJRMorrisHRMacIntyreI. Calcitonin gene-related peptide is a potent vasodilator. Nature. (1985) 313:54–6. doi:Ā 10.1038/313054a0

  • 54

    UddmanREdvinssonLEkbladEHĆ„kansonRSundlerF. Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects. Regul Pept. (1986) 15:1–23. doi:Ā 10.1016/0167-0115(86)90071-6

  • 55

    BrainSDGrantAD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev. (2004) 84:903–34. doi:Ā 10.1152/physrev.00037.2003

  • 56

    LiuTKamiyoshiASakuraiTIchikawa-ShindoYKawateHYangLet al. Endogenous calcitonin gene-related peptide regulates lipid metabolism and energy homeostasis in male mice. Endocrinology. (2017) 158:1194–206. doi:Ā 10.1210/en.2016-1510

  • 57

    WalkerCSLiXWhitingLGlyn-JonesSZhangSHickeyAJet al. Mice lacking the neuropeptide alpha-calcitonin gene-related peptide are protected against diet-induced obesity. Endocrinology. (2010) 151:4257–69. doi:Ā 10.1210/en.2010-0284

  • 58

    MooreMCLinDWColburnCAGoldsteinRENealDWCherringtonAD. Insulin- and glucagon-independent effects of calcitonin gene-related peptide in the conscious dog. Metabolism. (1999) 48:603–10. doi:Ā 10.1016/S0026-0495(99)90058-6

  • 59

    DanaherRNLoomesKMLeonardBLWhitingLHayDLXuLYet al. Evidence that alpha-calcitonin gene-related peptide is a neurohormone that controls systemic lipid availability and utilization. Endocrinology. (2008) 149:154–60. doi:Ā 10.1210/en.2007-0583

  • 60

    KuoTOuchiYKimSTobaKOrimoH. The role of activation of the sympathetic nervous system in the central pressor action of calcitonin gene-related peptide in conscious rats. Naunyn Schmiedebergs Arch Pharmacol. (1994) 349:394–400. doi:Ā 10.1007/BF00170886

  • 61

    SideriABakirtziKShihDQKoonHWFleshnerPArsenescuRet al. Substance P mediates pro-inflammatory cytokine release form mesenteric adipocytes in Inflammatory Bowel Disease patients. Cell Mol Gastroenterol Hepatol. (2015) 1:420–32. doi:Ā 10.1016/j.jcmgh.2015.03.003

  • 62

    MiegueuPSt-PierreDHLapointeMPoursharifiPLuHGuptaAet al. Substance P decreases fat storage and increases adipocytokine production in 3T3-L1 adipocytes. Am J Physiol Gastrointest Liver Physiol. (2013) 304:G420–7. doi:Ā 10.1152/ajpgi.00162.2012

  • 63

    KaragiannidesIStavrakisDBakirtziKKokkotouEPirtskhalavaTNayeb-HashemiHet al. (SP)-neurokinin-1 receptor (NK-1R) alters adipose tissue responses to high-fat diet and insulin action. Endocrinology. (2011) 152:2197–205. doi:Ā 10.1210/en.2010-1345

  • 64

    BordicchiaMLiuDAmriEZAilhaudGDessƬ-FulgheriPZhangCet al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. (2012) 122:1022–36. doi:Ā 10.1172/JCI59701

  • 65

    BiPShanTLiuWYueFYangXLiangXRet al. Inhibition of Notch signaling promotes browning of white adipose tissue and ameliorates obesity. Nat Med. (2014) 20:911–8. doi:Ā 10.1038/nm.3615

  • 66

    BaskaranPKrishnanVRenJThyagarajanB. Capsaicin induces browning of white adipose tissue and counters obesity by activating TRPV1 channel-dependent mechanisms. Br J Pharmacol. (2016) 173:2369–89. doi:Ā 10.1111/bph.13514

  • 67

    BaskaranPGustafsonNChavezN. TRPV1 Activation Antagonizes High-Fat Diet-Induced Obesity at Thermoneutrality and Enhances UCP-1 Transcription via PRDM-16. Pharm (Basel). (2024) 17:1098. doi:Ā 10.3390/ph17081098

  • 68

    QiangLWangLKonNZhaoWLeeSZhangYet al. Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ. Cell. (2012) 150:620–32. doi:Ā 10.1016/j.cell.2012.06.027

  • 69

    KrishnanVBaskaranPThyagarajanB. Troglitazone activates TRPV1 and causes deacetylation of PPARγ in 3T3-L1 cells. Biochim Biophys Acta Mol Basis Dis. (2019) 1865:445–53. doi:Ā 10.1016/j.bbadis.2018.11.004

  • 70

    VillanuevaCJVergnesLWangJDrewBGHongCTuYet al. Adipose subtype-selective recruitment of TLE3 or Prdm16 by PPARγ specifies lipid storage versus thermogenic gene programs. Cell Metab. (2013) 17:423–35. doi:Ā 10.1016/j.cmet.2013.01.016

  • 71

    SealePBjorkBYangWKajimuraSChinSKuangSet al. PRDM16 controls a brown fat/skeletal muscle switch. Nature. (2008) 454:961–7. doi:Ā 10.1038/nature07182

  • 72

    HesselinkMKMensinkMSchrauwenP. Human uncoupling protein-3 and obesity: an update. Obes Res. (2003) 11:1429–43. doi:Ā 10.1038/oby.2003.192

  • 73

    WhittleAJCarobbioSMartinsLSlawikMHondaresEVĆ”zquezMJet al. BMP8B increases brown adipose tissue thermogenesis through both central and peripheral actions. Cell. (2012) 149:871–85. doi:Ā 10.1016/j.cell.2012.02.066

  • 74

    GaoPJiangYWuHSunFLiYHeHet al. Inhibition of mitochondrial calcium overload by SIRT3 prevents obesity- or age-related whitening of brown adipose tissue. Diabetes. (2020) 69:165–80. doi:Ā 10.2337/db19-0526

  • 75

    KidaRYoshidaHMurakamiMShiraiMHashimotoOKawadaTet al. Direct action of capsaicin in brown adipogenesis and activation of brown adipocytes. Cell Biochem Funct. (2016) 34:34–41. doi:Ā 10.1002/cbf.3162

  • 76

    TangQQLaneMD. Adipogenesis: from stem cell to adipocyte. Annu Rev Biochem. (2012) 81:715–36. doi:Ā 10.1146/annurev-biochem-052110-115718

  • 77

    KajimuraSSealePSpiegelmanBM. Transcriptional control of brown fat development. Cell Metab. (2010) 11:257–62. doi:Ā 10.1016/j.cmet.2010.03.005

  • 78

    CannonBNedergaardJ. Brown adipose tissue: function and physiological significance. Physiol Rev. (2004) 84:277–359. doi:Ā 10.1152/physrev.00015.2003

  • 79

    KosticMKatoshevskiTSeklerI. Allosteric regulation of NCLX by mitochondrial membrane potential links the metabolic state and ca(2+) signaling in mitochondria. Cell Rep. (2018) 25:3465–75.e4. doi:Ā 10.1016/j.celrep.2018.11.084

  • 80

    LiLMaLLuoZWeiXZhaoYZhouCet al. Lack of TRPV1 aggravates obesity-associated hypertension through the disturbance of mitochondrial Ca2+ homeostasis in brown adipose tissue. Hypertens Res. (2022) 45:789–801. doi:Ā 10.1038/s41440-021-00842-8

  • 81

    ZhangLLYan LiuDMaLQLuoZDCaoTBZhongJet al. Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ Res. (2007) 100:1063–70. doi:Ā 10.1161/01.RES.0000262653.84850.8b

  • 82

    AbdillahAMYunJW. Capsaicin induces ATP-dependent thermogenesis via the activation of TRPV1/β3-AR/α1-AR in 3T3-L1 adipocytes and mouse model. Arch Biochem Biophys. (2024) 755:109975. doi: 10.1016/j.abb.2024.109975

  • 83

    LeeMSKimCTKimIHKimY. Effects of capsaicin on lipid catabolism in 3T3-L1 adipocytes. Phytother Res. (2011) 25:935–9. doi:Ā 10.1002/ptr.3339

  • 84

    MorimotoCKamedaKTsujitaTOkudaH. Relationships between lipolysis induced by various lipolytic agents and hormone-sensitive lipase in rat fat cells. J Lipid Res. (2001) 42:120–7. doi:Ā 10.1016/S0022-2275(20)32343-9

  • 85

    McGarryJDBrownNF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem. (1997) 244:1–14. doi:Ā 10.1111/j.1432-1033.1997.00001.x

  • 86

    RoussetSAlves-GuerraMCMozoJMirouxBCassard-DoulcierAMBouillaudFet al. The biology of mitochondrial uncoupling proteins. Diabetes. (2004) 53 Suppl 1:S130–5. doi:Ā 10.2337/diabetes.53.2007.S130

  • 87

    SharmaMDGarberAJFarmerJA. Role of insulin signaling in maintaining energy homeostasis. Endocr Pract. (2008) 14:373–80. doi:Ā 10.4158/EP.ep.14.3.373

  • 88

    CushmanSWWardzalaLJ. Potential mechanism of insulin action on glucose transport in the isolated rat adipose cell. Apparent translocation of intracellular transport systems to the plasma membrane. J Biol Chem. (1980) 255:4758–62. doi:Ā 10.1016/S0021-9258(19)85561-8

  • 89

    KolbH. Obese visceral fat tissue inflammation: from protective to detrimental? BMC Med. (2022) 20:494. doi:Ā 10.1186/s12916-022-02672-y

  • 90

    WoodsSCLotterECMcKayLDPorteDJr. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature. (1979) 282:503–5. doi:Ā 10.1038/282503a0

  • 91

    DerbenevAVZsombokA. Potential therapeutic value of TRPV1 and TRPA1 in diabetes mellitus and obesity. Semin Immunopathol. (2016) 38:397–406. doi:Ā 10.1007/s00281-015-0529-x

  • 92

    OlahZKaraiLIadarolaMJ. Protein kinase C(alpha) is required for vanilloid receptor 1 activation. Evidence for multiple signaling pathways. J Biol Chem. (2002) 277:35752–9. doi:Ā 10.1074/jbc.M201551200

  • 93

    ShibasakiTSunagaYFujimotoKKashimaYSeinoS. Interaction of ATP sensor, cAMP sensor, Ca2+ sensor, and voltage-dependent Ca2+ channel in insulin granule exocytosis. J Biol Chem. (2004) 279:7956–61. doi:Ā 10.1074/jbc.M309068200

  • 94

    TanakaHShimayaAKisoTKuramochiTShimokawaTShibasakiM. Enhanced insulin secretion and sensitization in diabetic mice on chronic treatment with a transient receptor potential vanilloid 1 antagonist. Life Sci. (2011) 88:559–63. doi:Ā 10.1016/j.lfs.2011.01.016

  • 95

    Van BurenJJBhatSRotelloRPauzaMEPremkumarLS. Sensitization and translocation of TRPV1 by insulin and IGF-I. Mol Pain. (2005) 1:17. doi:Ā 10.1186/1744-8069-1-17

  • 96

    SuriASzallasiA. The emerging role of TRPV1 in diabetes and obesity. Trends Pharmacol Sci. (2008) 29:29–36. doi:Ā 10.1016/j.tips.2007.10.016

  • 97

    TsuiHRazaviRChanYYanthaJDoschHM. ā€˜Sensing’ autoimmunity in type 1 diabetes. Trends Mol Med. (2007) 13:405–13. doi:Ā 10.1016/j.molmed.2007.07.006

  • 98

    PetterssonMAhrĆ©nBBƶttcherGSundlerF. Calcitonin gene-related peptide: occurrence in pancreatic islets in the mouse and the rat and inhibition of insulin secretion in the mouse. Endocrinology. (1986) 119:865–9. doi:Ā 10.1210/endo-119-2-865

  • 99

    RazaviRChanYAfifiyanFNLiuXJWanXYanthaJet al. TRPV1+ sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes. Cell. (2006) 127:1123–35. doi:Ā 10.1016/j.cell.2006.10.038

  • 100

    NobleMDRomacJWangYHsuJHumphreyJELiddleRA. Local disruption of the celiac ganglion inhibits substance P release and ameliorates caerulein-induced pancreatitis in rats. Am J Physiol Gastrointest Liver Physiol. (2006) 291:G128–34. doi:Ā 10.1152/ajpgi.00442.2005

  • 101

    ArnoldRAFowlerDKPetersJH. TRPV1 enhances cholecystokinin signaling in primary vagal afferent neurons and mediates the central effects on spontaneous glutamate release in the NTS. Am J Physiol Cell Physiol. (2024) 326:C112–c24. doi:Ā 10.1152/ajpcell.00409.2023

  • 102

    XuTYuZLiuYLuMGongMLiQet al. Hypoglycemic effect of electroacupuncture at ST25 through neural regulation of the pancreatic intrinsic nervous system. Mol Neurobiol. (2022) 59:703–16. doi:Ā 10.1007/s12035-021-02609-1

  • 103

    YuMTianHLuRQuanNQianL. TRPV1 promotes periodontitis tissue inflammation and oxidative damage by regulating STAT3 signaling pathway. J Periodontal Res. (2024). doi:Ā 10.1111/jre.13368

  • 104

    Van SlyckeSVan Den HeedeKVandenwyngaerdenE-A. Adrenal glands: anatomy, physiology, and pathophysiology. In: ShifrinALRaffaelliMRandolphGWGimmO, editors. Endocrine Surgery Comprehensive Board Exam Guide. Springer International Publishing, Cham (2021). p. 437–55.

  • 105

    DelarueCContesseVLengletSSicardFPerraudinVLefebvreHet al. Role of neurotransmitters and neuropeptides in the regulation of the adrenal cortex. Rev Endocr Metab Disord. (2001) 2:253–67. doi:Ā 10.1023/A:1011512415497

  • 106

    Ehrhart-BornsteinMHinsonJPBornsteinSRScherbaumWAVinsonGP. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev. (1998) 19:101–43. doi:Ā 10.1210/edrv.19.2.0326

  • 107

    ZouhalHJacobCDelamarchePGratas-DelamarcheA. Catecholamines and the effects of exercise, training and gender. Sports Med. (2008) 38:401–23. doi:Ā 10.2165/00007256-200838050-00004

  • 108

    BahnsenMBurrinJMJohnstonDGPernetAWalkerMAlbertiKG. Mechanisms of catecholamine effects on ketogenesis. Am J Physiol. (1984) 247:E173–80. doi:Ā 10.1152/ajpendo.1984.247.2.E173

  • 109

    SteinerKEStevensonRWAdkins-MarshallBACherringtonAD. The effects of epinephrine on ketogenesis in the dog after a prolonged fast. Metabolism. (1991) 40:1057–62. doi:Ā 10.1016/0026-0495(91)90130-O

  • 110

    NielsenTSJessenNJĆørgensenJOMĆøllerNLundS. Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease. J Mol Endocrinol. (2014) 52:R199–222. doi:Ā 10.1530/JME-13-0277

  • 111

    DongdemJTEtornamAEBeletaaSAliduIKoteyHWezenaCA. The β(3)-adrenergic receptor: structure, physiopathology of disease, and emerging therapeutic potential. Adv Pharmacol Pharm Sci. (2024) 2024:2005589. doi: 10.1155/2024/2005589

  • 112

    LafontanM. Kidney, adipose tissue, adipocytes–what’s new]? Nephrol Ther. (2011) 7:69–79. doi: 10.1016/j.nephro.2010.11.004

  • 113

    LafontanMBerlanM. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol Sci. (2003) 24:276–83. doi: 10.1016/S0165-6147(03)00132-9

  • 114

    RavussinELilliojaSKnowlerWCChristinLFreymondDAbbottWGet al. Reduced rate of energy expenditure as a risk factor for body-weight gain. N Engl J Med. (1988) 318:467–72. doi:Ā 10.1056/NEJM198802253180802

  • 115

    RavussinE. Energy metabolism in obesity. Studies in the Pima Indians. Diabetes Care. (1993) 16:232–8. doi:Ā 10.2337/diacare.16.1.232

  • 116

    SchoneveldOJGaemersICLamersWH. Mechanisms of glucocorticoid signalling. Biochim Biophys Acta. (2004) 1680:114–28. doi:Ā 10.1016/j.bbaexp.2004.09.004

  • 117

    BjƶrntorpP. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev. (2001) 2:73–86. doi: 10.1046/j.1467-789x.2001.00027.x

  • 118

    BjƶrntorpPRosmondR. Obesity and cortisol. Nutrition. (2000) 16:924–36. doi:Ā 10.1016/S0899-9007(00)00422-6

  • 119

    Ulrich-LaiYMHarding-RoseCAGuoABowlesWREngelandWC. ACTH inhibits the capsaicin-evoked release of CGRP from rat adrenal afferent nerves. Am J Physiol Regul Integr Comp Physiol. (2001) 280:R137–42. doi:Ā 10.1152/ajpregu.2001.280.1.R137

  • 120

    RosenfeldDSenkoAWMoonJYickIVarnavidesGGregurećDet al. Transgene-free remote magnetothermal regulation of adrenal hormones. Sci Adv. (2020) 6:eaaz3734. doi:Ā 10.1126/sciadv.aaz3734

  • 121

    KuramotoHKondoHFujitaT. Calcitonin gene-related peptide (CGRP)-like immunoreactivity in scattered chromaffin cells and nerve fibers in the adrenal gland of rats. Cell Tissue Res. (1987) 247:309–15. doi:Ā 10.1007/BF00218312

  • 122

    KobataKIwasawaTIwasakiYMoritaASuzukiYKikuzakiHet al. Capsaicinol: synthesis by allylic oxidation and its effect on TRPV1-expressing cells and adrenaline secretion in rats. Biosci Biotechnol Biochem. (2006) 70:1904–12. doi:Ā 10.1271/bbb.60064

  • 123

    SongWLuoQZhangYZhouLLiuYMaZet al. Organic cation transporter 3 (Oct3) is a distinct catecholamines clearance route in adipocytes mediating the beiging of white adipose tissue. PloS Biol. (2019) 17:e2006571. doi:Ā 10.1371/journal.pbio.2006571

  • 124

    UchidaKDezakiKYoneshiroTWatanabeTYamazakiJSaitoMet al. Involvement of thermosensitive TRP channels in energy metabolism. J Physiol Sci. (2017) 67:549–60. doi:Ā 10.1007/s12576-017-0552-x

  • 125

    Arribas-BlÔzquezMOlivos-OréLABarahonaMVSÔnchez de la MuelaMSolarVJiménezEet al. Overexpression of P2X3 and P2X7 receptors and TRPV1 channels in adrenomedullary chromaffin cells in a rat model of neuropathic pain. Int J Mol Sci. (2019) 20:155. doi: 10.3390/ijms20010155

  • 126

    Oi-KanoYIwasakiYNakamuraTWatanabeTGotoTKawadaTet al. Oleuropein aglycone enhances UCP1 expression in brown adipose tissue in high-fat-diet-induced obese rats by activating β-adrenergic signaling. J Nutr Biochem. (2017) 40:209–18. doi:Ā 10.1016/j.jnutbio.2016.11.009

  • 127

    OotsukaYKulasekaraKde MenezesRCBlessingWW. SR59230A, a beta-3 adrenoceptor antagonist, inhibits ultradian brown adipose tissue thermogenesis and interrupts associated episodic brain and body heating. Am J Physiol Regul Integr Comp Physiol. (2011) 301:R987–94. doi:Ā 10.1152/ajpregu.00085.2011

  • 128

    WatanabeTSakuradaNKobataK. Capsaicin-, resiniferatoxin-, and olvanil-induced adrenaline secretions in rats via the vanilloid receptor. Biosci Biotechnol Biochem. (2001) 65:2443–7. doi:Ā 10.1271/bbb.65.2443

  • 129

    IwasakiYTanabeMKobataKWatanabeT. TRPA1 agonists–allyl isothiocyanate and cinnamaldehyde–induce adrenaline secretion. Biosci Biotechnol Biochem. (2008) 72:2608–14. doi: 10.1271/bbb.80289

  • 130

    BlaakEEVan BaakMAKemerinkGJPakbiersMTHeidendalGASarisWH. Beta-adrenergic stimulation of energy expenditure and forearm skeletal muscle metabolism in lean and obese men. Am J Physiol. (1994) 267:E306–15. doi:Ā 10.1152/ajpendo.1994.267.2.E306

  • 131

    LandsbergLSavilleMEYoungJB. Sympathoadrenal system and regulation of thermogenesis. Am J Physiol. (1984) 247:E181–9. doi:Ā 10.1152/ajpendo.1984.247.2.E181

  • 132

    KobayashiAOsakaTNambaYInoueSLeeTHKimuraS. Capsaicin activates heat loss and heat production simultaneously and independently in rats. Am J Physiol. (1998) 275:R92–8. doi:Ā 10.1152/ajpregu.1998.275.1.R92

  • 133

    Himms-HagenJCuiJDanforthEJr.TaatjesDJLangSSWatersBLet al. Effect of CL-316,243, a thermogenic beta 3-agonist, on energy balance and brown and white adipose tissues in rats. Am J Physiol. (1994) 266:R1371–82. doi:Ā 10.1152/ajpregu.1994.266.4.R1371

  • 134

    NagaseIYoshidaTKumamotoKUmekawaTSakaneNNikamiHet al. Expression of uncoupling protein in skeletal muscle and white fat of obese mice treated with thermogenic beta 3-adrenergic agonist. J Clin Invest. (1996) 97:2898–904. doi:Ā 10.1172/JCI118748

  • 135

    LeeYHMottilloEPGrannemanJG. Adipose tissue plasticity from WAT to BAT and in between. Biochim Biophys Acta. (2014) 1842:358–69. doi:Ā 10.1016/j.bbadis.2013.05.011

  • 136

    WuJBostrƶmPSparksLMYeLChoiJHGiangAHet al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell. (2012) 150:366–76. doi:Ā 10.1016/j.cell.2012.05.016

  • 137

    KozakLP. The genetics of brown adipocyte induction in white fat depots. Front Endocrinol (Lausanne). (2011) 2:64. doi:Ā 10.3389/fendo.2011.00064

  • 138

    CollinsSYehuda-ShnaidmanEWangH. Positive and negative control of Ucp1 gene transcription and the role of β-adrenergic signaling networks. Int J Obes (Lond). (2010) 34 Suppl 1:S28–33. doi:Ā 10.1038/ijo.2010.180

  • 139

    CaoWDanielKWRobidouxJPuigserverPMedvedevAVBaiXet al. p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene. Mol Cell Biol. (2004) 24:3057–67. doi:Ā 10.1128/MCB.24.7.3057-3067.2004

  • 140

    RimJSKozakLP. Regulatory motifs for CREB-binding protein and Nfe2l2 transcription factors in the upstream enhancer of the mitochondrial uncoupling protein 1 gene. J Biol Chem. (2002) 277:34589–600. doi:Ā 10.1074/jbc.M108866200

  • 141

    FerreiraLGBPrevattoJPFreitasHRReisRAMSilvaPMRMartinsMAet al. Capsaicin inhibits lipopolysaccharide-induced adrenal steroidogenesis by raising intracellular calcium levels. Endocrine. (2019) 64:169–75. doi:Ā 10.1007/s12020-019-01849-5

  • 142

    KoivistoAPVoetsTIadarolaMJSzallasiA. Targeting TRP channels for pain relief: A review of current evidence from bench to bedside. Curr Opin Pharmacol. (2024) 75:102447. doi:Ā 10.1016/j.coph.2024.102447

  • 143

    QiaoZLiuSZhaiWJiangLMaYZhangZet al. Novel dual-target FAAH and TRPV1 ligands as potential pharmacotherapeutics for pain management. Eur J Med Chem. (2024) 267:116208. doi:Ā 10.1016/j.ejmech.2024.116208

  • 144

    MoranMMSzallasiA. Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field. Br J Pharmacol. (2018) 175:2185–203. doi:Ā 10.1111/bph.14044

  • 145

    SzallasiACortrightDNBlumCAEidSR. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov. (2007) 6:357–72. doi:Ā 10.1038/nrd2280

  • 146

    SzallasiABlumbergPM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev. (1999) 51:159–212. doi:Ā 10.1016/S0031-6997(24)01403-0

  • 147

    BƶlcskeiKTĆ©kusVDĆ©zsiLSzolcsĆ”nyiJPethoG. Antinociceptive desensitizing actions of TRPV1 receptor agonists capsaicin, resiniferatoxin and N-oleoyldopamine as measured by determination of the noxious heat and cold thresholds in the rat. Eur J Pain. (2010) 14:480–6. doi: 10.1016/j.ejpain.2009.08.005

  • 148

    RoundPPriestleyARobinsonJ. An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol. (2011) 72:921–31. doi:Ā 10.1111/j.1365-2125.2011.04040.x

  • 149

    HeymsfieldSBWaddenTA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. (2017) 376:254–66. doi:Ā 10.1056/NEJMra1514009

  • 150

    KalarchianMAMarcusMDCourcoulasAPChengYLevineMD. Self-report of gastrointestinal side effects after bariatric surgery. Surg Obes Relat Dis. (2014) 10:1202–7. doi:Ā 10.1016/j.soard.2014.08.007

  • 151

    GramDXHansenAJWilkenMElmTSvendsenOCarrRDet al. Plasma calcitonin gene-related peptide is increased prior to obesity, and sensory nerve desensitization by capsaicin improves oral glucose tolerance in obese Zucker rats. Eur J Endocrinol. (2005) 153:963–9. doi:Ā 10.1530/eje.1.02046

  • 152

    BaskaranPMarkertLBennisJZimmermanLFoxJThyagarajanB. Assessment of pharmacology, safety, and metabolic activity of capsaicin feeding in mice. Sci Rep. (2019) 9:8588. doi:Ā 10.1038/s41598-019-45050-0

  • 153

    PaternosterSFalascaM. Dissecting the physiology and pathophysiology of glucagon-like peptide-1. Front Endocrinol (Lausanne). (2018) 9:584. doi:Ā 10.3389/fendo.2018.00584

  • 154

    KumarVMahajanNKharePKondepudiKKBishnoiM. Role of TRPV1 in colonic mucin production and gut microbiota profile. Eur J Pharmacol. (2020) 888:173567. doi:Ā 10.1016/j.ejphar.2020.173567

  • 155

    SongJXRenHGaoYFLeeCYLiSFZhangFet al. Dietary capsaicin improves glucose homeostasis and alters the gut microbiota in obese diabetic ob/ob mice. Front Physiol. (2017) 8:602. doi:Ā 10.3389/fphys.2017.00602

  • 156

    ChoiSEKimTHYiSAHwangYCHwangWSChoeSJet al. Capsaicin attenuates palmitate-induced expression of macrophage inflammatory protein 1 and interleukin 8 by increasing palmitate oxidation and reducing c-Jun activation in THP-1 (human acute monocytic leukemia cell) cells. Nutr Res. (2011) 31:468–78. doi:Ā 10.1016/j.nutres.2011.05.007

  • 157

    DevesaIPlanells-CasesRFernĆ”ndez-BallesterGGonzĆ”lez-RosJMFerrer-MontielAFernĆ”ndez-CarvajalA. Role of the transient receptor potential vanilloid 1 in inflammation and sepsis. J Inflammation Res. (2011) 4:67–81. doi: 10.2147/JIR.S12978

  • 158

    HuangJZhangXMcNaughtonPA. Inflammatory pain: the cellular basis of heat hyperalgesia. Curr Neuropharmacol. (2006) 4:197–206. doi:Ā 10.2174/157015906778019554

  • 159

    WannerSPGaramiARomanovskyAA. Hyperactive when young, hypoactive and overweight when aged: connecting the dots in the story about locomotor activity, body mass, and aging in Trpv1 knockout mice. Aging (Albany NY). (2011) 3:450–4. doi:Ā 10.18632/aging.100306

  • 160

    WesterterpKRPlasquiG. Physically active lifestyle does not decrease the risk of fattening. PloS One. (2009) 4:e4745. doi: 10.1371/journal.pone.0004745

Summary

Keywords

transient receptor potential vanilloid subtype 1 (TRPV1), obesity, neuromodulatory mechanisms, endocrine mechanisms, energy metabolism

Citation

Wang J, Liu M, Wen L, Xing P, Chen J, Xia X and Ding W (2025) Role of TRPV1 in neuroendocrine regulation: a potential target against obesity?. Front. Immunol. 16:1598804. doi: 10.3389/fimmu.2025.1598804

Received

24 March 2025

Accepted

19 June 2025

Published

03 July 2025

Volume

16 - 2025

Edited by

Robson Xavier Faria, Oswaldo Cruz Foundation (Fiocruz), Brazil

Reviewed by

Marilia Zaluar P. Guimaraes, Federal University of Rio de Janeiro, Brazil

Bin Xu, Nanjing University of Chinese Medicine, China

Updates

Copyright

*Correspondence: WeiJun Ding, ; Xiuwen Xia,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics